1. Home
  2. TNGX

TNGX

Tango Therapeutics Inc.

Logo Tango Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 3:32pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Founded: 2014 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 787.6M IPO Year: N/A
Target Price: $17.25 AVG Volume (30 days): 610.7K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.08 EPS Growth: N/A
52 Week Low/High: $2.47 - $13.03 Next Earning Date: 05-07-2024
Revenue: $36,527,000 Revenue Growth: 46.93%
Revenue Growth (this year): -21.67% Revenue Growth (next year): 5.16%

Share on Social Networks: